Arbor Pharmaceuticals, Inc. clinical trials

Acquired by Azurity Pharmaceuticals

The registry lists 15 studies whose lead sponsor is Arbor Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2025.

Studies

Recruiting first, then most recently updated. Showing 15 of 15. All Azurity Pharmaceuticals studies →

• Vigilant ObservatIon of GlIadeL WAfer ImplaNT RegistryCompletedNCT02684838

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With HypertensionCompletedNCT02235909Phase 3

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine SulfateCompletedNCT03659929Phase 3

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug UsersCompletedNCT06097676Phase 4

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid UsersCompletedNCT06247488Phase 4

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09TerminatedNCT02027155Phase 1

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom SettingCompletedNCT01986062Phase 4

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)TerminatedNCT02074007Phase 3

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil TabletsCompletedNCT02522208Phase 1

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Relative Bioavailability of AR10 Compared to Reference ProductCompletedNCT02723669Phase 1

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)TerminatedNCT02049164Phase 2

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• AR08 for Treatment of ADHD in ChildrenCompletedNCT01876719Phase 2

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human VolunteersCompletedNCT01587313Phase 1

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Study of FAECC Scale (Modified FLACC) to Evaluate Ear Pain in Children With Acute Otitis MediaCompletedNCT01588535Phase 2

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group

• Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis MediaCompletedNCT02044341Phase 3

  Sponsor listed in the registry: Arbor Pharmaceuticals, Inc. · Arbor Pharmaceuticals, Inc. — acquired company within the Azurity Pharmaceuticals group